Importantly, small molecule inhibition of CDK2 does not induce a clean arrest in the G1phase of the cell cycle, but instead it leads to a G2/M block or an intra-S phase arrest, which is the outcome of treatment with various toxic chemotherapeutic agents that lead to cell death (45,57)

Importantly, small molecule inhibition of CDK2 does not induce a clean arrest in the G1phase of the cell cycle, but instead it leads to a G2/M block or an intra-S phase arrest, which is the outcome of treatment with various toxic chemotherapeutic agents that lead to cell death (45,57). IRI. Despite reduced epithelial proliferation, PD 0332991 ameliorated kidney injury as reflected by improved serum creatinine and blood urea nitrogen levels 24 h after injury. Inflammatory markers and macrophage infiltration were significantly decreased in injured kidneys 3 days following IRI. These results indicate that induction of proximal tubule cell cycle arrest with specific CDK4/6 inhibitors, or pharmacological quiescence, represents a novel strategy to prevent AKI. Keywords:cell cycle, cyclin-dependent kinase, acute kidney injury, proximal tubule, ischemia-reperfusion injury acute p44erk1 kidney injury(AKI) is a potentially devastating, increasingly common, and costly syndrome characterized by sudden impairment of kidney function as a result of a toxic or ischemic insult (9,23,61,67). Patients with AKI experience increased length of hospital stay, increased mortality, and increased risk of future development of chronic kidney disease (CKD) and end-stage renal disease (4,7,22,28,38,66). Clinical outcomes are directly related to AKI severity, including even minor changes in serum creatinine (27). Even apparently reversible AKI resulting from contrast exposure or cardiothoracic surgery is associated with increased long-term risk of mortality (13,18,68). The combination of potentially severe and long-lasting outcomes related to AKI leads to high cumulative cost of care, with annual estimations of AKI-associated costs at $10 billion in the United States (7,9). There are currently no authorized therapeutics directly indicated to prevent or treat AKI and connected systemic maladies, and novel treatments are urgently needed. Ischemia and toxins can cause AKI in humans (1,30,40,41,51,54,71) and bilateral ischemia-reperfusion injury (Bi-IRI) is definitely a widely approved mouse model of human being AKI (69). Within the 1st 24 h following injury, tubular cells undergo apoptotic and necrotic cell death. In response, the surviving, normally quiescent proximal tubule epithelial cells rapidly proliferate, and 70% of these cells enter the S phase of the cell cycle (19,20). Accompanying this strong proliferative response is definitely DNA damage resulting from the postischemic, inflammatory environment (46). A very similar sequence of events can be induced by nephrotoxicants such as cisplatin WYE-125132 (WYE-132) (37,47,54). Cyclin-dependent kinases 2/4/6 (CDK 2/4/6) mediate cell cycle checkpoint progression from G1to S phase. Binding of their activating subunits, the D-type cyclins for CDK4/6 and the E- or A-type cyclins for CDK2, causes cell cycle progression into S phase via phosphorylation of the retinoblastoma protein (Rb) (35,57). Significant recent work has shown cell types differ in their need for CDK4/6 vs. CDK2 activity for proliferation, with many cell types capable of briskly dividing actually in the absence of CDK4/6 or D-type cyclin activity (26,3234,70). Of particular relevance, it is also now obvious that some cell types in adult mammals (e.g., pancreatic beta cells, hematopoetic stem and progenitor cells) totally require CDK4/6 activity to traverse G1 (24,48,49). While epithelial cell cycle reentry after injury has traditionally been considered an appropriate restoration response to the loss of adjacent cells after an initial insult, recent evidence suggests a more complicated picture. Epithelial cell cycle inhibition in vitro, whether through overexpression of the CDK inhibitor p21CIP, or through broad spectrum small molecule CDK inhibitors, WYE-125132 (WYE-132) can actually protect against cisplatin-induced cell death (36,45,47). One of these broad spectrum CDK inhibitors, purvalanol, has been used in vivo to afford safety from cisplatin-induced AKI (47). The p21CIPCDK inhibitor is definitely induced in response to DNA damage and other tensions, and mice lacking p21CIPexhibit exacerbated kidney ischemic injury, consistent with the hypothesis that cell cycle inhibition postinsult protects against AKI (36,42). Importantly, small molecule inhibition of CDK2 WYE-125132 (WYE-132) does not induce a clean arrest in the G1phase of the cell cycle, but instead it prospects to a G2/M block or an intra-S phase arrest, which is the end result of treatment with numerous toxic chemotherapeutic providers that lead to cell death (45,57). Also, while CDK2 inhibition gives protection in the short term, G2/M arrest would likely be an undesirable long-term effect as it has been recently reported that this induces progressive interstitial fibrosis in the kidney and improved cell apoptosis (69). Furthermore, the currently available small molecule inhibitors of CDK2 are known to nonspecifically inhibit several other kinases in the.